Eli Lilly's Kisunla has been approved in Japan for early symptomatic Alzheimer's disease, following its US approval in July ...

Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 594.50% and ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

(RTTNews) - Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare ...

Eli Lilly on Tuesday said Japan's Ministry of Health, Labour and Welfare Japan approved Kisunla for adults with early symptomatic Alzheimer's, including those with mild cognitive impairment as well as ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Two new drug treatments prove effective in forestalling the start of early onset Alzheimer's; Roskamp will eventually offer ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

As the 2024 presidential election approaches, the rival campaigns have promised to “lower costs” on healthcare for people living in the United States. Unfortunately, whether the winner after Nov. 5 is ...